Metal complexes and therapeutic uses thereof
AssigneesUniversity of Western Sydney, The University of Sydney
InventorsRonald Ralph Fenton, Janice Aldrich-Wright
Life of this patent
Estimating the term…
Abstract
A compound of formula I or a salt thereof [ML1L2]2+ (I) where M is selected from the group consisting of platinum(II), palladium (II) and copper(II); L1 is an intercalator moiety; and L2 is a bidentate ligand, provided that when L2 is other than a bidentate ligand containing an aryl or phenyl group, L2 is a chiral bidentate ligand.
Claims39
A compound of formula I or a salt thereof
- [ML1L2]2+ I
- where M is selected from the group consisting of platinum(II), palladium (II) and copper(II);
- L1 is 1,10-phenanthroline or an alkyl-substituted derivative thereof;
- and L2 is a chiral diamine ligand.
A method of treatment of a cancer in a subject comprising administering to the subject a therapeutically effective amount of a compound of formula I or a salt thereof
- [ML1L2]2+ I
- where M is selected from the group consisting of platinum(II), palladium (II) and copper(II);
- L1 is 1,10-phenanthroline or an alkyl-substituted derivative thereof;
- and
- L2 is a chiral diamine ligand,
- wherein the cancer is testicular, ovarian, breast, bladder, head and neck, lung, colon, neoblastoma, or epidermoid cancer.
A pharmaceutical composition comprising a compound in accordance with formula I
- [ML1L2]2+ I
- where M is selected from the group consisting of platinum(II), palladium (II) and copper(II);
- L1 is 1,10-phenanthroline or an alkyl-substituted derivative thereof;
- and
- L2 is a chiral diamine ligand,
- in an amount sufficient to have an antitumour effect in an animal or human together with at least one pharmaceutically acceptable excipient, diluent and/or carrier.
Dependencies are inferred from the claim text.